Skip to main content
. Author manuscript; available in PMC: 2018 Jul 15.
Published in final edited form as: Cancer Res. 2017 May 31;77(14):3894–3907. doi: 10.1158/0008-5472.CAN-17-0468

Figure 7.

Figure 7

Therapeutic effect of combining Delta-24-RGDOX and anti-PD-L1 antibody. A, A cartoon depiction of the treatment scheme. i.c.: intracranial; i.t.: intratumoral. B, Survival plots of the treatment groups (n = 20, except n = 19 for PBS, n = 18 for D24-RGDOX + IgG). C, Complete tumor regression induced by the combination of Delta-24-RGDOX and anti-PD-L1 antibody (α-PD-L1) in long-term surviving mice. A representative hematoxylin and eosin-stained, whole-mount coronal mouse brain section (left, sacrificed on day 104 after tumor implantation) from the long-term surviving mice treated with the combination is shown. The arrow marks a residue dent left by the screw for guiding the tumor implantation and viral injections. Tumor sequel (marked with dashed lines in the left panel, also enlarged image on the right) is present at the tumor implantation site. D, Survival plots of the group treated with Delta-24-RGDOX together with α-PD-L1 in B when re-challenged with GL261-5 in the contralateral hemisphere rather than the hemisphere with the originally treated tumor. Naive: n = 10; Survivor: n = 6. * P ≤ 0.0001, log-rank test. D24-RGDOX: Delta-24-RGDOX.